Molecular Partners AG ADR
Yahoo Finance • last year
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
MP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironment MP0317 monotherapy shows a favorable safety profile up to the highest planned doses Patient recruitment of... Full story
Yahoo Finance • last year
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
MP0533 shows acceptable safety profile in first three dose cohorts (5 patients total, data cut-off July 20); reported adverse reactions are of Grade 1/2 and no dose-limiting toxicity observed to dateEmerging evidence of antitumor activity... Full story
Yahoo Finance • last year
Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio
MP0317 Phase 1 dose escalation recruitment completed in patients with advanced solid tumors; updated clinical results to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2023 MP0533 Phase 1/2a recru... Full story
Yahoo Finance • last year
Molecular Partners Reports H1 2023 Corporate Highlights and Financials
Phase 1/2a clinical trial of tetraspecific T cell engager candidate MP0533 initiated in patients with relapsed/refractory AML and MDS/AML; dosing ongoing in the 4th dose cohort; initial data expected in Q4 2023 Positive MP0317 data of ong... Full story
Yahoo Finance • last year
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 19, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin th... Full story
Yahoo Finance • 2 years ago
Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin the... Full story
Yahoo Finance • 2 years ago
Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin t... Full story
Yahoo Finance • 2 years ago
Molecular Partners Full Year 2022 Earnings: Beats Expectations
Molecular Partners (VTX:MOLN) Full Year 2022 Results Key Financial Results Revenue: CHF189.6m (up by CHF179.8m from FY 2021). Net income: CHF117.9m (up from CHF63.8m loss in FY 2021). Profit margin: 62% (up from net loss in FY 2021). The... Full story
Yahoo Finance • 2 years ago
Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR : Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of... Full story
Yahoo Finance • 2 years ago
Molecular Partners Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML
New data indicates potential to expand the therapeutic window and improve safety compared to existing T-cell engagers Tri-specific T-cell engager resulted in AML cell-specific cytotoxicity with minimal off-tumor toxicityPhase I clinical tr... Full story
Yahoo Finance • 2 years ago
Molecular Partners Announces Planned Departure of Chief Financial Officer
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of c... Full story
Yahoo Finance • 2 years ago
Interim Management Statement Q3 2022: Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of c... Full story
Yahoo Finance • 2 years ago
Molecular Partners AG Investors: Last Days to Actively Participate in the Class Action Lawsuit; September 12, 2022 Deadline; Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Molecular Partners AG (“Molecular Partners” or “the Company”) (NASDAQ... Full story
Yahoo Finance • 2 years ago
MOLN Class Action Complaint Filed: Johnson Fistel, Globally-Recognized Law Firm Encourages Shareholders to Submit Their Molecular Partners Losses
SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Molecular Partners AG (“Molecular Partners” or the “Company”) (NA... Full story
Yahoo Finance • 2 years ago
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Molecular Partners, TG Therapeutics, 17EdTech, and Enochian and Encourages Investors to Contact the Firm
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Molecular Partners AG (N... Full story
Yahoo Finance • 2 years ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Molecular Partners AG of Class Action Lawsuit and Upcoming Deadline – MOLN
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Molecular Partners AG (“Molecular Partners” or the “Company”) (NASDAQ: MOLN) and certain of its officers and director... Full story
Yahoo Finance • 2 years ago
ROSEN, A TOP RANKED LAW FIRM, Encourages Molecular Partners AG Investors to Secure Counsel Before Important Deadline in Securities Class Action – MOLN
NEW YORK, Sept. 04, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Molecular Partners AG (NASDAQ: MOLN): (i) pursuant and/or traceable to the offering documents is... Full story
Yahoo Finance • 2 years ago
U, OM & MOLN Class Actions Reminder: Bronstein, Gewirtz & Grossman, LLC, A Top Class Action Firm, Reminds Investors to Contact the Firm and Actively Participate
NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of... Full story
Yahoo Finance • 2 years ago
Investors who Lost over $100,000 in Molecular Partners AG (NASDAQ: MOLN) shares should contact the Shareholders Foundation in connection with pending Lawsuit
SAN DIEGO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in Molecular Partners AG (NASDAQ: MOLN) shares. Investors with losses more than $100,000 in shares o... Full story
Yahoo Finance • 2 years ago
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Missfresh, Molecular Partners, TG Therapeutics, and 17EdTech and Encourages Investors to Contact the Firm
NEW YORK, Aug. 26, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Missfresh Limited (NASDAQ... Full story
